Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
Stopped early · Phase 2
Conditions studied: EBV Lymphomas, Lympho-proliferative Diseases
In brief
The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.
Key facts
- Study ID
- NCT00917826
- Run by
- HemaQuest Pharmaceuticals Inc.
- People needed
- 1
- Starts
- 2008-09-01
- Last updated by the study team
- 2011-08-01
Who can join
Age: 3 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 3 years. (No dosing or adverse event data are currently available on the use of valganciclovir in patients < 16 years of age.)
- Life expectancy of > 3 months.
- ECOG Performance Status 0-2 or Karnofsky Performance Scale ≥ 60%.
- Baseline (untransfused) HbF level > 2%
- Normal organ and marrow function defined as: (i) absolute neutrophil count of ≥ 1,000/µL. (ii) platelets ≥ 50,000/ µL. (iii) total bilirubin of ≤ 2.0 x upper limit of normal. (iv) AST (SGOT)/ALT(SGPT) of ≤ 2.0 x institutional upper limit of normal. (v) creatinine within normal range for institution.
- Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.
- Able and willing to give informed consent.
You may not qualify if…
- Patients that have received chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entry, or those who have not recovered form adverse events due to agents administered 4 weeks earlier.
- Patients may not be receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Arginine Butyrate, ganciclovir or valganciclovir.
- Patients who have an acute myocardial infarction or onset of atrial fibrillation within the past 6 months.
- Uncontrolled intercurrent illness including, but not limited to , ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Tumor impinging on an organ or anatomical structure deemed critical by the investigator.
- Pregnant women.
Where it is running
- Hackensack University Medical Center — Hackensack, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.